查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951340

內視鏡逆行性胰造影市場 - 全球產業規模、佔有率、趨勢、機會及預測（依產品、手術、最終用戶、地區及競爭格局分類），2021-2031年

Endoscopic Retrograde Cholangiopancreatography Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product, By Procedure, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球內視鏡逆行性造影(ERCP) 市場預計將從 2025 年的 22.3 億美元成長到 2031 年的 36.9 億美元，複合年成長率為 8.76%。

內視鏡逆行性造影）是一種特殊的醫療程序，它結合了上消化道內視鏡檢查和放射影像技術，用於診斷胰膽管病變。該市場的成長主要受全球人口老化和膽道疾病發病率上升的驅動。這些因素促使人們需要進行治療干預，從而維持了對高效診斷和治療方案的需求，進而推動了該行業的經濟發展。

市場概覽
預測期 2027-2031
市場規模：2025年 22.3億美元
市場規模：2031年 36.9億美元
複合年成長率：2026-2031年 8.76%
成長最快的細分市場 內視鏡治療設備
最大的市場 北美洲

然而，該行業面臨許多挑戰，包括具備安全開展這項複雜手術所需專業知識的醫生數量有限。熟練專業人員的短缺可能導致服務瓶頸，並限制手術量，尤其是在新興市場。根據美國癌症協會的數據，預計到2025年，美國將新增約67,440例胰臟癌病例，這項數據凸顯了此類治療方法的迫切需求。因此，儘管醫療專業人員短缺，但持續的疾病負擔仍然是推動內視鏡治療方案持續應用的關鍵因素。

市場促進因素

隨著醫療機構將感染預防和營運效率置於優先地位，並消除重複使用裝置帶來的交叉感染風險，一次性十二指腸鏡的應用正在不斷擴大。這項轉變的驅動力來自監管指南以及省去複雜再處理流程帶來的經濟效益（降低醫院的整體擁有成本）。根據Amb A/S公司於2025年11月發布的2024/25年度報告，該公司內視鏡解決方案部門實現了15.4%的內部成長。這一數字表明，隨著醫療機構更換老舊設備以提高病患安全，一次性技術的應用正在迅速普及。

此外，膽道和胰臟疾病發生率的上升是推動全球內視鏡檢查數量增加的主要臨床因素。生活方式的改變和人口老化等因素導致惡性腫瘤和膽結石的發生率上升，因此需要精確的治療和診斷干預。正如美國國立衛生研究院 (NIH) 於 2025 年 2 月發布的題為《全球胰腺癌發病率趨勢》的論文中所述，預計 2022 年全球胰腺癌新發病例將達到約 510,922 例，並持續成長。為了應對這一流行病學趨勢，製造商正在擴大產能。波士頓科學公司 (Boston Scientific) 的 2025 年報告預測，其 2024 年全年淨銷售額將達到 167.5 億美元，比上年成長 17.6%。這一成長歸功於產品系列的強勁表現。

市場挑戰

全球內視鏡逆行性造影（ERCP）市場面臨的主要障礙之一是合格的ERCP操作人員短缺。由於該技術需要大量的專業培訓和精湛的技術，因此合格的從業人員數量仍然有限。隨著胰膽疾病發生率的上升，醫療基礎設施無法相應擴大人力資源，造成了嚴重的瓶頸。這種短缺導致患者等待時間延長和手術量減少，這直接阻礙了市場的產生收入。

此外，ERCP（內視鏡逆行性胰膽管攝影）學習曲線陡峭，令許多年輕醫生望而卻步，也給現有的醫療團隊帶來了額外的壓力。醫療界的人口結構變化加劇了這種壓力。根據美國醫學院協會預測，到2036年，美國醫療系統將面臨高達8.6萬名醫生的缺口，將嚴重影響胃腸病學等複雜專科的發展。治療性介入需求與熟練內視鏡醫師供應之間的差距日益擴大，限制了市場成長，尤其是在教育基礎設施本就薄弱的發展中地區和醫療資源匱乏地區。

市場趨勢

人工智慧（AI）在影像分析領域的應用正成為內視鏡逆行性胰膽管攝影術（ERCP）領域的一項變革性技術，顯著提升了手術決策和診斷準確性。這些先進的演算法能夠輔助內視鏡醫師即時鑑別不明原因的狹窄並檢測膽道病變，從而最大限度地減少傳統透視判讀中固有的觀察者間差異。除了診斷之外，這項技術還在不斷發展，用於預測術後併發症，從而實現更個人化的患者照護。美國醫學會在2025年1月發布的《數位健康趨勢全國調查報告》中指出，到2024年，將有66%的醫生採用人工智慧工具，比前一年成長78%，顯示數據驅動型解決方案在胃腸病學領域正迅速普及。

同時，高清視覺化系統和數位膽道鏡市場也取得了顯著進展。這一趨勢標誌著影像診斷方式正從間接放射成像轉向直接成像，使臨床醫生能夠在複雜碎石術和精準切片檢查中直接、清晰地觀察胰管和膽管。臨床上對這些先進光學平台的需求日益成長，源於需要處理棘手的結石負荷，並在無需重複手術的情況下準確分期惡性腫瘤。Olympus Corporation在2024年11月發布的截至2024年9月的會計年度中期財務報告中指出，其內視鏡解決方案業務的銷售額成長了10.3%，這印證了上述需求。這一成長主要得益於歐洲和北美地區先進視覺化系統的強勁銷售。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球內視鏡逆行性胰造影市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（內視鏡、內視鏡治療設備、視覺化系統、能量設備、其他）
    • 依手術方式分類（膽道括約肌切開術、膽道支架置入術、膽道擴張術、胰管括約肌切開術、胰管支架置入術、胰管擴張術）
    • 依最終用戶（醫院、門診機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美內視鏡逆行性胰造影市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲內視鏡逆行性胰造影市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區內視鏡逆行性胰造影市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東與非洲內視鏡逆行性胰造影市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲內視鏡逆行性胰造影市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球內視鏡逆行性胰造影市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Olympus Corporation
  • CONMED Corporation
  • Boston Scientific Corporation
  • Medtronic PLC
  • TeleMed Systems, Inc.
  • Ambu A/S
  • FUJIFILM Holdings Corporation
  • HOBBS MEDICAL INC
  • Cook Group Incorporated
  • HOYA Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25450

The Global Endoscopic Retrograde Cholangiopancreatography Market is projected to expand from a valuation of USD 2.23 Billion in 2025 to USD 3.69 Billion by 2031, reflecting a compound annual growth rate of 8.76%. As a specialized medical intervention, Endoscopic Retrograde Cholangiopancreatography integrates upper gastrointestinal endoscopy with radiographic imaging to address pathologies within the pancreatic and bile ducts. This market trajectory is primarily propelled by an aging global demographic and an increasing incidence of biliary disorders, factors that necessitate therapeutic measures and sustain the demand for efficient diagnostic and treatment solutions, thereby underpinning the sector's financial progress.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.23 Billion
Market Size 2031USD 3.69 Billion
CAGR 2026-20318.76%
Fastest Growing SegmentEndotherapy Devices
Largest MarketNorth America

Conversely, the industry confronts a significant obstacle regarding the limited availability of physicians possessing the expertise to safely execute this intricate procedure. This shortage of skilled professionals threatens to create service bottlenecks and restrict the volume of procedures, particularly within emerging markets. Data from the American Cancer Society indicates that approximately 67,440 individuals in the United States will receive a pancreatic cancer diagnosis in 2025, a statistic that underscores the urgent need for these interventions. Consequently, the persistent burden of disease remains a critical factor fueling the continued utilization of endoscopic solutions despite workforce constraints.

Market Driver

The increasing implementation of single-use duodenoscopes is significantly reshaping the market as healthcare facilities emphasize infection prevention and operational efficiency to eliminate cross-contamination risks linked to reusable instruments. This shift is accelerated by regulatory guidance and the economic advantages of discarding complex reprocessing procedures, which lowers the overall cost of ownership for hospitals. According to the 'Annual Report 2024/25' published by Ambu A/S in November 2025, the company achieved an organic growth rate of 15.4 percent within its Endoscopy Solutions division, a figure that highlights the rapid transition toward disposable technologies as institutions upgrade legacy equipment to improve patient safety.

Additionally, the rising incidence of biliary and pancreatic conditions acts as the central clinical force increasing the global volume of endoscopic procedures. Factors such as lifestyle shifts and an aging population are leading to higher rates of malignancies and gallstones, requiring accurate therapeutic and diagnostic interventions. As noted by the National Institutes of Health in the February 2025 article 'Trends in the Global Incidence of Pancreatic Cancer', the global disease burden involved an estimated 510,922 new cases in the 2022 reference year, with forecasts suggesting a continuing rise. This epidemiological trend drives manufacturers to expand capabilities, reflected in Boston Scientific's 2025 report of 16.75 billion dollars in full-year 2024 net sales, a 17.6 percent increase attributed to strong medical and surgical portfolio performance.

Market Challenge

A primary hurdle facing the Global Endoscopic Retrograde Cholangiopancreatography Market is the shortage of medical professionals qualified to perform ERCP procedures. Because this technique demands extensive specialized training and a high degree of technical skill, the number of capable practitioners remains limited. As the incidence of pancreatic and biliary disorders grows, the inability of healthcare infrastructures to expand their workforce proportionally creates severe bottlenecks. These deficiencies result in extended patient wait times and diminished procedure volumes, factors that directly impede the market's revenue generation capabilities.

Moreover, the steep learning curve required for ERCP dissuades many emerging physicians from pursuing this specialty, placing further strain on the current workforce. This pressure is compounded by demographic changes within the medical community itself. According to the Association of American Medical Colleges, the United States healthcare system was projected in 2024 to encounter a physician shortage of up to 86,000 by 2036, a deficit that critically affects complex fields such as gastroenterology. This growing disparity between the demand for therapeutic interventions and the supply of skilled endoscopists limits market growth, particularly in developing and underserved areas where educational infrastructure is already sparse.

Market Trends

The incorporation of artificial intelligence into image analysis is emerging as a transformative element in the ERCP sector, significantly improving procedural decision-making and diagnostic accuracy. These sophisticated algorithms assist endoscopists in differentiating indeterminate strictures and detecting biliary lesions in real-time, thereby minimizing the inter-observer variability inherent in conventional fluoroscopic interpretation. Beyond diagnostics, this technology is evolving to forecast post-procedure complications, facilitating more tailored patient care. In a January 2025 national survey report on digital health trends, the American Medical Association noted that 66 percent of physicians employed artificial intelligence tools in 2024, a 78 percent increase from the prior year that illustrates the rapid adoption of data-driven solutions in gastroenterology.

Concurrently, the market is experiencing significant progress in high-definition visualization systems and digital cholangioscopy. This trend represents a major shift away from indirect radiographic imaging, enabling clinicians to obtain clear, direct views of the pancreatic and bile ducts for complex lithotripsy and precise biopsies. The escalating clinical demand for these advanced optical platforms stems from the need to manage difficult stone burdens and accurately stage malignancies without resorting to repeated procedures. Evidence of this demand is found in Olympus Corporation's 'Consolidated Financial Results for the Six Months Ended September 30, 2024', released in November 2024, which reported a 10.3 percent revenue increase in its Endoscopic Solutions Business, driven largely by strong sales of advanced visualization systems in Europe and North America.

Key Market Players

  • Olympus Corporation
  • CONMED Corporation
  • Boston Scientific Corporation
  • Medtronic PLC
  • TeleMed Systems, Inc.
  • Ambu A/S
  • FUJIFILM Holdings Corporation
  • HOBBS MEDICAL INC
  • Cook Group Incorporated
  • HOYA Corporation

Report Scope

In this report, the Global Endoscopic Retrograde Cholangiopancreatography Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endoscopic Retrograde Cholangiopancreatography Market, By Product

  • Endoscopes
  • Endotherapy Devices
  • Visualization Systems
  • Energy Devices
  • Others

Endoscopic Retrograde Cholangiopancreatography Market, By Procedure

  • Biliary Sphincterotomy
  • Biliary Stenting
  • Biliary Dilatation
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Stenting
  • Pancreatic Duct Dilation

Endoscopic Retrograde Cholangiopancreatography Market, By End User

  • Hospitals
  • Outpatient Facilities

Endoscopic Retrograde Cholangiopancreatography Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endoscopic Retrograde Cholangiopancreatography Market.

Available Customizations:

Global Endoscopic Retrograde Cholangiopancreatography Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endoscopic Retrograde Cholangiopancreatography Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others)
    • 5.2.2. By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation)
    • 5.2.3. By End User (Hospitals, Outpatient Facilities)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Endoscopic Retrograde Cholangiopancreatography Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Procedure
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Procedure
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Procedure
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Procedure
        • 6.3.3.2.3. By End User

7. Europe Endoscopic Retrograde Cholangiopancreatography Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Procedure
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Procedure
        • 7.3.1.2.3. By End User
    • 7.3.2. France Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Procedure
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Procedure
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Procedure
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Procedure
        • 7.3.5.2.3. By End User

8. Asia Pacific Endoscopic Retrograde Cholangiopancreatography Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Procedure
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Procedure
        • 8.3.1.2.3. By End User
    • 8.3.2. India Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Procedure
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Procedure
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Procedure
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Procedure
        • 8.3.5.2.3. By End User

9. Middle East & Africa Endoscopic Retrograde Cholangiopancreatography Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Procedure
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Procedure
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Procedure
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Procedure
        • 9.3.3.2.3. By End User

10. South America Endoscopic Retrograde Cholangiopancreatography Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Procedure
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Procedure
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Procedure
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Endoscopic Retrograde Cholangiopancreatography Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Procedure
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Endoscopic Retrograde Cholangiopancreatography Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Olympus Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. CONMED Corporation
  • 15.3. Boston Scientific Corporation
  • 15.4. Medtronic PLC
  • 15.5. TeleMed Systems, Inc.
  • 15.6. Ambu A/S
  • 15.7. FUJIFILM Holdings Corporation
  • 15.8. HOBBS MEDICAL INC
  • 15.9. Cook Group Incorporated
  • 15.10. HOYA Corporation

16. Strategic Recommendations

17. About Us & Disclaimer